DaVita Revenue 2011-2025 | DVA
DaVita annual/quarterly revenue history and growth rate from 2011 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- DaVita revenue for the quarter ending September 30, 2025 was $3.420B, a 4.8% increase year-over-year.
- DaVita revenue for the twelve months ending September 30, 2025 was $13.318B, a 5.14% increase year-over-year.
- DaVita annual revenue for 2024 was $12.816B, a 5.56% increase from 2023.
- DaVita annual revenue for 2023 was $12.14B, a 4.57% increase from 2022.
- DaVita annual revenue for 2022 was $11.61B, a 0.08% decline from 2021.
|
DaVita Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $12,816 |
| 2023 | $12,140 |
| 2022 | $11,610 |
| 2021 | $11,619 |
| 2020 | $11,551 |
| 2019 | $11,388 |
| 2018 | $11,405 |
| 2017 | $10,877 |
| 2016 | $10,707 |
| 2015 | $9,982 |
| 2014 | $12,795 |
| 2013 | $11,764 |
| 2012 | $8,186 |
| 2011 | $6,732 |
| 2010 | $6,220 |
|
DaVita Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2025-09-30 | $3,420 |
| 2025-06-30 | $3,380 |
| 2025-03-31 | $3,224 |
| 2024-12-31 | $3,295 |
| 2024-09-30 | $3,264 |
| 2024-06-30 | $3,187 |
| 2024-03-31 | $3,071 |
| 2023-12-31 | $3,146 |
| 2023-09-30 | $3,121 |
| 2023-06-30 | $3,000 |
| 2023-03-31 | $2,873 |
| 2022-12-31 | $2,917 |
| 2022-09-30 | $2,949 |
| 2022-06-30 | $2,927 |
| 2022-03-31 | $2,818 |
| 2021-12-31 | $2,944 |
| 2021-09-30 | $2,938 |
| 2021-06-30 | $2,917 |
| 2021-03-31 | $2,820 |
| 2020-12-31 | $2,905 |
| 2020-09-30 | $2,924 |
| 2020-06-30 | $2,880 |
| 2020-03-31 | $2,841 |
| 2019-12-31 | $2,899 |
| 2019-09-30 | $2,904 |
| 2019-06-30 | $2,843 |
| 2019-03-31 | $2,743 |
| 2018-12-31 | $2,821 |
| 2018-09-30 | $2,847 |
| 2018-06-30 | $2,887 |
| 2018-03-31 | $2,849 |
| 2017-12-31 | $2,781 |
| 2017-09-30 | $2,765 |
| 2017-06-30 | $2,699 |
| 2017-03-31 | $2,631 |
| 2016-12-31 | $-322 |
| 2016-09-30 | $3,731 |
| 2016-06-30 | $3,718 |
| 2016-03-31 | $3,581 |
| 2015-12-31 | $-266 |
| 2015-09-30 | $3,526 |
| 2015-06-30 | $3,435 |
| 2015-03-31 | $3,288 |
| 2014-12-31 | $3,328 |
| 2014-09-30 | $3,252 |
| 2014-06-30 | $3,172 |
| 2014-03-31 | $3,043 |
| 2013-12-31 | $3,063 |
| 2013-09-30 | $3,000 |
| 2013-06-30 | $2,872 |
| 2013-03-31 | $2,830 |
| 2012-12-31 | $2,478 |
| 2012-09-30 | $1,946 |
| 2012-06-30 | $1,913 |
| 2012-03-31 | $1,850 |
| 2011-12-31 | $1,750 |
| 2011-09-30 | $1,758 |
| 2011-06-30 | $1,661 |
| 2011-03-31 | $1,562 |
| 2010-12-31 | $1,424 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $8.581B | $12.816B |
| DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quest Diagnostics (DGX) | United States | $20.797B | 19.35 |
| Encompass Health (EHC) | United States | $11.416B | 21.95 |
| Elanco Animal Health (ELAN) | United States | $10.479B | 21.97 |
| Chemed (CHE) | United States | $6.169B | 21.67 |
| RadNet (RDNT) | United States | $5.798B | 197.76 |
| Option Care Health (OPCH) | United States | $4.510B | 19.20 |
| LifeStance Health (LFST) | United States | $2.490B | 0.00 |
| Addus HomeCare (ADUS) | United States | $2.016B | 20.81 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.765B | 22.24 |
| Astrana Health (ASTH) | United States | $1.212B | 113.32 |
| U.S Physical Therapy (USPH) | United States | $1.090B | 27.57 |
| Atai Beckley N.V (ATAI) | Germany | $0.935B | 0.00 |
| Pennant (PNTG) | United States | $0.861B | 28.62 |
| Daxor (DXR) | United States | $0.063B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.057B | 0.00 |
| Psychemedics (PMD) | United States | $0.000B | 0.00 |